NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $0.90 -0.02 (-1.88%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.91 +0.01 (+0.93%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tevogen Bio Stock (NASDAQ:TVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$0.90▼$0.9450-Day Range$0.87▼$1.2652-Week Range$0.26▼$3.09Volume370,052 shsAverage Volume1.45 million shsMarket Capitalization$177.55 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. Read More Tevogen Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreTVGN MarketRank™: Tevogen Bio scored higher than 77% of companies evaluated by MarketBeat, and ranked 241st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTevogen Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Tevogen Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.86% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.86% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.00 News SentimentTevogen Bio has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Tevogen Bio this week, compared to 4 articles on an average week.Search Interest6 people have searched for TVGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,768,993.00 in company stock.Percentage Held by Insiders73.24% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tevogen Bio's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGN Stock News HeadlinesTevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 28 at 10:57 AM | finanznachrichten.deTevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term ValueAugust 27 at 3:30 PM | quiverquant.comQREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 29 at 2:00 AM | Weiss Ratings (Ad)Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 27 at 3:20 PM | globenewswire.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityAugust 26 at 5:28 PM | markets.businessinsider.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityAugust 26 at 2:50 PM | globenewswire.comTevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025August 25, 2025 | quiverquant.comQTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsAugust 25, 2025 | globenewswire.comSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $1.03 at the beginning of 2025. Since then, TVGN stock has decreased by 12.4% and is now trading at $0.9026. How were Tevogen Bio's earnings last quarter? Tevogen Bio Holdings Inc. (NASDAQ:TVGN) posted its quarterly earnings results on Tuesday, August, 19th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tevogen Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tevogen Bio investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings8/19/2025Today8/29/2025Next Earnings (Estimated)11/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Tevogen Bio$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+1,007.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.73 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-775.49% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-10.03Miscellaneous Outstanding Shares196,705,000Free Float52,638,000Market Cap$177.55 million OptionableN/A Beta-0.77 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TVGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.